New abstracts show the oral PCSK9 inhibitor cut LDL-C by 57% to 63% across PREVENT risk groups, with reductions maintained in an extension study.

Many patients who stop a GLP-1 RA regain weight. How plans can measure adherence when cash-pay fills go unseen.

In more than 250,000 adults with prediabetes and obesity, GLP-1 users had lower risks of type 2 diabetes, death, and cardiovascular events.

In nearly 443,000 US adults, both low-frequency and heavy cannabis use were linked to higher odds of cardiovascular disease, led by stroke.

Patients on tegoprubart reported fewer transplant-related symptoms and better quality of life at 12 months than those on tacrolimus in phase 2 BESTOW.

Kidney Week 2026 brought strong IgAN data, looked back on 5 years of value-based kidney care, and highlighted evidence of persistent CKD care gaps.

Norah Terrault, MD, MPH, on why few diagnosed patients reach HCV cure and how primary care test-and-treat can close the gap.